Författare: Rak Sabina
Titel: Mekanismerna vid allergenspecifik immunterapi klarnar (serie: Tema immunterapi vid astma/allergi) 2008 nr 26 sid 1935-7
Ämnesord:
Desensibilisering, immunologisk
Allergener
Överkänslighet
Sök liknande artiklar
Referenser:
1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1.1572-3
2. Calderon NA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection
immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews
2007; (1): CD001936.
3. Abramson MJ, Puy RM, Weiner JM. Allergen immuntherapy for asthma. Cochrane
Database of Systematic Review 2003;(4): CD001186
4. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients
during immunotherapy that modulate IgE synthesis. J of Allergy Clin Immunol 1987;79_591-
8
5. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more.
Immunol Today 1996;17:138-146
6. Kapsenberg ML, Jansen HM, Bos JD, Wierenga E. Role of type 1 and type2 T helper cells in allergic diseases. Curr. Opinion Immunol 1992;4:788-94
7. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanism of immunotherapy. J Allergy Clin Immunol 2004;113:1025-34
8. Robinson DS, Larche M, Durham SR. Treg and allergic disease. J Clin Invest
2004;114:1389-97
9. Jutel M, Akdis M, Budak F, Aerbischer-Casaulta C, Wszyszcz M, Blazer K, Akdis C. IL- 10 and TGF-_ cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-14
10. Movérare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush
immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy
Asthma Immunol. 2001 Mar;86(3):337-42
11. Djurup R, Malling HJ, High IgG4 antibody level is associated with failure of
immunotherapy with inhalant allergens. Clin Allergy 1987;17:459-68
12. Wachholz PA, Durham SR. Induction of “blocking” antibodies during immunotherapy. Clin Exp Allergy 2003;33:1171-1174
13. Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of
ultrarush venom immunotherapy on the IgG antibody response Allergy 2000;55:455-462
14. Pilette C, Nouri-Aria KT. Jacobson MR. Wilcock LK, Detry B, Walker SM, Francis JN,
Durham SR. Grass pollen immunotherapy induces an Allergen-Specific IgA2 antibody
Response Associated with Mucosal TGF-_ Expression. Journal of immunology
2007;178:4658-4666
15. Arvidsson MB, Lövhagen O. Rak S . Allergen specific immunotherapy attenuates early
and late phase reactions in lower airways of birch pollen asthmatic patients:
a double blind placebo-controlled study. Allergy 2004;59:74-80
16. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR IL-9 and c-Kit+ mast
cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy.J Allergy
Clin Immunol. 2005 Jul;116(1):73- 80
17. Plewako H, Arvidsson M, Oancea I, Hasseus B, Dahlgren U, Rak S. The effect of specific
immunotherapy on the expression of costimulatory molecules in late phase reaction of the
skin in allergic patients. Clin Exp Allergy 2004; 34:1862-1867
18. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB,
Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T
lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing
messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996 Jun;97(6):1356-65
19. Rak S, Löwhagen O, Venge P. The effect of immunotherapy on bronchial
hyperresponsiveness and eosinophil cationic protein in pollen allergic patients.
J Allergy Clin Immunol 1988;82:470-480.
20. Rak S, Björnsson A, Håkanson L, Sörenson S, Venge P. The effect of immunotherapy on
eosinophil accumulation and production of eosinophil chemotactic activity in the lung of
subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991;88:878-88
21. Kay AB. Overview of 'allergy and allergic diseases: with a view to the future'. Br Med
Bull 2000;56:843-64
22. Gabrielsson S, Söderlund A, Paulie S,. van der Pouw Kraan T. C.T.M, Troye-Blomberg
M.and Rak S. Allergen immunotherapy prevents increased levels of allergen specific IL-4
and IL-13 producing cells during pollen season. Allergy 2001;56:293-300.
23. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy J Allergy Clin Immunol. 1998 Aug;102(2):157-64
24. Grindebacke H, Wing K, Andersson A-C, Suri-Payer E, Rak S, Rudin A.
Defective suppression of Th2 cytokines by CD4+CD25+ regulatory T cells in birch allergy.
Clin Exp Allergy. 2004 Sep;34(9):1364-72..
25. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS.
Sublingual immunotherapy: a comprehensive review.
J Allergy Clin Immunol. 2006 May;117(5):1021-35
26. Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy 2006;Suppl. 81:11-14
27. Savolainen J, Laaksonen K, Rantio-Lehtimäki A, Terho EO. Increased expression of
allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood
mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy.
2004 Mar;34(3):413-9
28. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates
allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006;61:1184-90
